Sansure Supports Sierra Leone in Achieving a Historic Breakthrough in Cervical Cancer Prevention and Control
Recently, Sierra Leone achieved a significant breakthrough in cervical cancer prevention and control. The country’s first-ever cervical cancer HPV screening project results announcement and award ceremony was held at the Ministry of Health of Sierra Leone. The project was led by the 25th batch of the Chinese (Hunan) medical aid team to Sierra Leone, with Sansure Biotech supplying HPV screening reagents, instruments, as well as technical support and laboratory guidance. Its successful implementation has not only been highly commended by the Sierra Leonean government but also earned unanimous accolades from international organizations such as the United Nations Population Fund (UNFPA) and the World Health Organization (WHO).
The groundbreaking initiative, led by Dr. Chen Zhihui of the Chinese medical team, aimed to address the high prevalence of cervical cancer, particularly among HIV-positive women. Over the course of the project, the team conducted HPV screenings across nine districts and 30 clinics, providing critical insights into early detection, prevention, and treatment. For over two months, Sansure’s technicians overcame critical challenges—including power shortages and limited laboratory conditions—to successfully conduct over 8,000 assays, ensuring the accuracy and reliability of all experimental data. The project’s systematic analysis of infections across different populations offers valuable insights to help the Sierra Leonean government formulate more effective cervical cancer prevention and control policies.
To honor the organizations and individuals who made outstanding contributions to cervical cancer prevention in Sierra Leone, an award ceremony was jointly organized by the UNFPA, the Ministry of Health of Sierra Leone, and the Chinese Embassy in Sierra Leone. The Hunan Provincial Health Commission was presented with the “Outstanding Contribution Award for Public Health Services,” Dr. Chen Zhihui, the project leader, received the “National Award for Outstanding Contribution to Cervical Cancer Prevention and Control,” and Sansure Biotech was honored with the “National Public Health Contribution Award.” This reflects the high-level international recognition of Sansure’s precise and accessible solutions, further enhancing the company’s influence in global public health.
Building on the project’s research results, Sansure will collaborate with the project team to further develop HPV screening tools tailored to Sierra Leone’s local conditions, with plans for nationwide implementation. This initiative aims to substantially increase cervical cancer screening coverage in Sierra Leone, while reducing both incidence and mortality rates.
For the first time, the Beijing Action Plan (2025-2027), signed at the 2024 Forum on China-Africa Cooperation (FOCAC), outlines China’s commitment to assisting African countries in combating infectious diseases and cervical cancer, through the sharing of clinical and disease prevention technologies, alongside strategic project support. This initiative aligns with the United Nations 2030 Sustainable Development Agenda, aiming to eliminate preventable diseases and improve health outcomes across Africa.
As a leading enterprise in the life sciences sector, Sansure is actively answering the call of the “Forum on China-Africa Cooperation (FOCAC)—Beijing Action Plan”. The company continues to drive technological innovation and strengthen international collaboration, striving to provide Chinese wisdom and precise, accessible Sansure solutions to contribute more to public health advancements in Africa.
